China Pharmaceutical: Subsidiary Receives Marketing Approval for Mupirocin API

date
20/11/2026
China Meheco announced that its wholly-owned subsidiary Tianfang Pharmaceutical has received the Marketing Application Approval Notification for the chemical API mupirocin issued by the National Medical Products Administration, and that the drug meets the relevant drug registration requirements and has been approved for registration. Mupirocin is mainly used for skin and soft tissue infections caused by Gram-positive cocci. Tianfang Pharmaceutical has invested approximately RMB 5.86 million in this drug cumulatively. This approval will further expand the company's product portfolio and improve its layout of biofermentation API products. Future sales of this drug may carry the risk of falling short of expectations.